Permira funds to acquire European CNS specialty pharmaceutical company Neuraxpharm
Financial details of the transaction were not disclosed. With its unique understanding of the CNS market built over 35 years, Neuraxpharm develops and commercializes value-added medicines and consumer
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.